Head-To-Head Contrast: Regulus Therapeutics (RGLS) and Codexis (CDXS)
Regulus Therapeutics (NASDAQ: RGLS) and Codexis (NASDAQ:CDXS) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, institutional ownership, risk, valuation, dividends, earnings and analyst recommendations.
This table compares Regulus Therapeutics and Codexis’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a summary of current recommendations and price targets for Regulus Therapeutics and Codexis, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Regulus Therapeutics presently has a consensus price target of $4.10, indicating a potential upside of 228.00%. Codexis has a consensus price target of $6.94, indicating a potential upside of 4.32%. Given Regulus Therapeutics’ higher probable upside, equities research analysts clearly believe Regulus Therapeutics is more favorable than Codexis.
Institutional & Insider Ownership
21.9% of Regulus Therapeutics shares are owned by institutional investors. Comparatively, 63.6% of Codexis shares are owned by institutional investors. 4.8% of Regulus Therapeutics shares are owned by company insiders. Comparatively, 9.8% of Codexis shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Volatility & Risk
Regulus Therapeutics has a beta of 1.6, indicating that its stock price is 60% more volatile than the S&P 500. Comparatively, Codexis has a beta of -1.37, indicating that its stock price is 237% less volatile than the S&P 500.
Valuation and Earnings
This table compares Regulus Therapeutics and Codexis’ gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Regulus Therapeutics||$257,999.00||502.84||-$73.96 million||($1.54)||-0.81|
|Codexis||$43.16 million||7.45||-$15.16 million||($0.41)||-16.22|
Codexis has higher revenue and earnings than Regulus Therapeutics. Codexis is trading at a lower price-to-earnings ratio than Regulus Therapeutics, indicating that it is currently the more affordable of the two stocks.
Codexis beats Regulus Therapeutics on 10 of the 13 factors compared between the two stocks.
Regulus Therapeutics Company Profile
Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state. The Company’s Regulus microMarkers division is focused on identifying microRNAs as biomarkers of human disease. It has a research collaboration with Biogen focused on the discovery of microRNAs as biomarkers for multiple sclerosis and has completed research for another pharmaceutical company to explore microRNAs as biomarkers for specific patient populations. The Company is developing RG-101, an N-Acetylgalactosamine (GalNAc)-conjugated anti-miR targeting miR-122; RG-012, an anti-miR targeting microRNA-21 for the treatment of Alport syndrome, and RG-125, a GalNAc-conjugated anti-miR targeting microRNA-103/107.
Codexis Company Profile
Codexis, Inc. is a developer of biocatalysts for the pharmaceutical and fine chemicals markets. The Company’s CodeEvolver protein engineering technology platform, which introduces genetic mutations into genes in order to give rise to changes in the enzymes that they produce, overcomes many of the limitations, allowing customers to evolve and optimize biocatalysts to perform specific and desired chemical reactions at commercial scale. The Company’s pharmaceutical products include enzymes, pharmaceutical intermediates, active pharmaceutical ingredients (APIs) and Codex Biocatalyst Panels and Kits. The fine chemicals market consists of several market verticals, including food and food ingredients, animal feed, flavors and fragrances, and agricultural chemicals. The Company also uses its technology to develop an early stage, enzyme therapeutic product candidate for the treatment of phenylketonuria (PKU) in humans through oral administration.
Receive News & Ratings for Regulus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.